Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside

Shafiqur Rahman, Ph.D. is Professor of Pharmacology in the Department of Pharmaceutical Sciences at South Dakota State University (SDSU) in Brookings, USA. He received his Ph.D. in Neuropharmacology from the Memorial University of Newfoundland, Canada. Dr. Rahman completed his post-doctoral fellowship in the Department of Psychiatry from Indiana University School of Medicine in Indianapolis in USA. Prior to joining SDSU, he worked as research scientist and faculty at the University of Kentucky in Lexington, USA and the University of Toronto, Canada. Dr. Rahman's research focus is drug discovery in neuropharmacology, i.e. the development of novel therapeutic candidates for the treatment of alcohol/nicotine addiction and neuropsychiatric disorders using animal models. His research resulted in over 200 publications/presentations, including peer-reviewed scientific articles, reviews, book chapters, meeting abstracts and seminar presentations. Dr. Rahman served on numerous scientific review panels and editorial boards of several scientific Journals. He has authored or edited multiple books or Journals in drug addiction and neuropharmacology field. Dr. Rahman is also affiliated with a number of professional organizations, including Society for Neuroscience and American Society for Pharmacology and Experimental Therapeutics.

• 1. Novel targets for parkinsonism-depression comorbidityYousef Tizabi, Bruk Getachew, Antonei B. Csoka, Kebreten F. Manaye and Robert L. Copeland2. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findingsSonja Elsaid, Stefan Kloiber and Bernard Le Foll3. Stress, psychiatric disorders, molecular targets, and moreFatin Atrooz, Hesong Liu and Samina Salim4. Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's diseaseRamsha Shams, Naren L. Banik and Azizul Haque5. Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disordersPatrick J. Ronan, Sarah A. Flynn and Thomas P. Beresford6. Emerging evidence for the role of pituitary adenylate cyclase-activating peptide in neuropsychiatric disordersKabirullah Lutfy and Shankar Gollapudi7. Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunitiesShafiqur Rahman and Sami Alzarea8. Its complicated: The relationship between alcohol and microglia in the search for novel pharmacotherapeutic targets for alcohol use disordersJennifer K. Melbourne, K. Ryan Thompson, Hui Peng and Kimberly Nixon9. Microglia as possible therapeutic targets for autism spectrum disordersMegumi Andoh, Yuji Ikegaya and Ryuta Koyama